Stock listing

NASDAQ:RNA Atrium Therapeutics, Inc. Stock

Home listing (NASDAQ) of Atrium Therapeutics, Inc.

Follow Atrium Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:RNA

$6.92 USD +0.28 (+4.2%)

Close on Nov 20, 2026

Since Feb 27, 2026 -53.1% · daily closes, Feb 27, 2026 – Nov 20, 2026, adjusted for splits
Day range
$6.88 – $7.44 USDNov 20, 2026
Volume
319,656 sharesNov 20, 2026
Market cap
$118.4M USDAt the close on Nov 20, 2026 · price × 17.11M shares outstanding
Traded on an average day
$2.73M USDMedian day 220,812 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Atrium Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:RNA · Home$6.92 USD+0.28 (+4.2%)319,656$7.01$7.44$6.875$6.64Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:RNA · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$6.92+0.28+4.2%$7.01$7.44$6.875319,656
$6.64+0.16+2.5%$6.46$6.78$6.45220,812
$6.48+0.05+0.8%$6.46$6.945$6.445352,218
$6.43-1.08-14.4%$7.54$7.69$6.36337,582
$7.51+0.01+0.1%$7.71$7.83$7.47195,172
$7.50-0.46-5.8%$7.89$7.89$7.49294,716
$7.96-0.27-3.3%$8.23$8.26$7.93130,118
$8.23-0.15-1.8%$8.30$8.40$8.11108,814
$8.38+0.04+0.5%$8.42$8.463$8.20138,121
$8.34+0.02+0.2%$8.32$8.55$8.23108,189
$8.32-0.36-4.1%$8.68$8.73$8.29193,893
$8.68-0.04-0.5%$8.85$8.99$8.50136,789
$8.72+0.17+2.0%$8.57$8.77$8.45280,927
$8.55+0.28+3.4%$8.22$8.64$8.185470,071
$8.27+0.01+0.1%$8.19$8.31$7.88566,641
$8.26-0.14-1.7%$8.52$8.65$8.20155,777
$8.40+0.08+1.0%$8.14$8.45$8.14233,598
$8.32+0.27+3.4%$8.05$8.39$8.05198,572
$8.05-0.15-1.8%$8.20$8.23$7.98187,418
$8.20+0.04+0.5%$8.06$8.21$7.78192,660
$8.16+0.16+2.0%$8.01$8.185$7.945173,482
$8.00+0.02+0.3%$7.97$8.32$7.96193,208
$7.98+0.37+4.9%$7.75$8.27$7.71289,488
$7.61-0.06-0.8%$7.68$7.87$7.49243,913
$7.67-0.15-1.9%$7.79$8.06$7.67190,978
$7.82+0.14+1.8%$7.75$7.87$7.64131,236
$7.68-0.07-0.9%$7.75$7.935$7.54269,494
$7.75-0.46-5.6%$8.22$8.22$7.75237,187
$8.21-0.19-2.3%$8.40$8.482$8.2187,396
$8.40+0.14+1.7%$8.29$8.50$8.135208,348
$8.26+0.33+4.2%$8.15$8.325$7.965649,309
$7.93-0.06-0.8%$7.95$8.13$7.9391,818
$7.99+0.02+0.3%$8.00$8.07$7.78411,686
$7.97+0.13+1.7%$7.83$8.105$7.63268,285
$7.84-0.30-3.7%$8.22$8.421$7.68533,805
$8.14-0.14-1.7%$8.30$8.44$7.96395,723
$8.28-0.14-1.7%$8.38$8.46$8.22197,306
$8.420.000.0%$8.42$8.50$8.21158,804
$8.42+0.13+1.6%$8.21$8.515$8.05504,915
$8.29+0.10+1.2%$8.20$8.365$8.10221,427
$8.19-0.14-1.7%$8.30$8.49$8.16355,242
$8.33-0.89-9.7%$9.22$9.31$8.29434,524
$9.22+0.03+0.3%$9.24$9.485$9.17241,277
$9.19+0.24+2.7%$8.97$9.34$8.943481,266
$8.95-0.61-6.4%$9.57$9.665$8.661,036,990
$9.56+0.06+0.6%$9.65$9.695$9.435569,619
$9.50-0.59-5.8%$10.11$10.11$9.50356,436
$10.09-0.12-1.2%$10.21$10.21$9.62274,580
$10.21-0.15-1.4%$10.37$10.71$10.15255,714
$10.36+0.01+0.1%$10.37$10.41$10.00247,499
$10.35-0.16-1.5%$10.44$10.74$10.28421,628
$10.51-0.84-7.4%$11.20$11.20$10.34690,444
$11.35-2.84-20.0%$14.08$14.19$10.751,722,578
$14.19-0.41-2.8%$14.51$14.65$14.01167,785
$14.60+0.54+3.8%$14.19$14.68$13.99164,905
$14.06+0.29+2.1%$13.77$14.10$13.76111,641
$13.77+0.45+3.4%$13.24$13.92$13.20178,705
$13.32-0.32-2.3%$13.53$13.55$13.1097,048
$13.64-0.34-2.4%$13.87$13.95$13.51108,637
$13.98+0.13+0.9%$13.78$14.09$13.59120,562
$13.85-0.15-1.1%$13.93$14.07$13.66179,349
$14.00+0.38+2.8%$13.72$14.05$13.41166,578
$13.62+0.42+3.2%$13.27$13.64$13.04140,555
$13.20-0.28-2.1%$13.53$13.59$12.96180,677
$13.48-0.23-1.7%$13.75$13.88$13.20218,806
Ticker
NASDAQ:RNA
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Atrium Therapeutics, Inc. news

Atrium Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
16 in the last 12 months · 139 in all · newest Nov 12, 2026 · oldest 2020
Decks
3 decks · latest Nov 12, 2026

Where Atrium Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:RNA · Home listing · This pageNASDAQUnited StatesUSD
BOATS:RNABOATSUnited StatesUSD

Valuation

EV/sales −2.9× against a median of 13.6×: the lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$113.0M USD
P/E
Loss
EV/sales
−2.9×
EV/EBITDA
Negative EBITDA
Price/book
0.6×
Gross margin
42.2%
Operating margin
−243.6%
Net margin
−229.7%
Debt to equity
0.0×
Beta vs S&P 500
0.76

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Atrium Therapeutics, Inc. · NASDAQ:RNAUS$118.4M−US$113.0Mn/a−2.9×n/a0.6×−229.7%0.0×0.76
Invivyd, Inc. · NASDAQ:IVVDUS$122.0MUS$3.86Mn/a0.1×n/a0.8×−214.8%0.1×2.06
Satellos Bioscience Inc · TSX:MSCLUS$121.9MUS$69.24Mn/an/an/a2.5×n/a0.0×0.49
Alar Pharmaceuticals Inc · TPEX:6785US$121.0MUS$51.67Mn/a568×n/a1.7×n/a0.0×n/a
CANbridge Pharmaceuticals Inc. · HKEX:1228US$120.4MUS$111.5Mn/a13.4×n/an/a−146.4%n/an/a
STCube, Inc. · KRX:052020US$118.4MUS$72.43Mn/a13.6×n/a2.6×−338.7%0.0×n/a
Adagene, Inc. · NASDAQ:ADAGUS$118.2M−US$3.65Mn/a−0.5×n/a1.1×−229.6%0.1×1.43
Curacle Co., Ltd. · KRX:365270US$117.6MUS$100.4Mn/a16.3×n/a3.4×−92.1%0.0×n/a
PegBio Co., Ltd. Class H · HKEX:2565US$117.2MUS$55.97Mn/an/an/a2.9×n/a0.0×n/a
enGene Therapeutics Inc. · NASDAQ:ENGNUS$116.6M−US$149.7Mn/an/an/a0.5×n/a0.0×1.82
Sinew Pharma, Inc. · TPEX:6634US$114.4MUS$84.23Mn/a59,064×n/a3.6×n/a0.0×n/a
Median of the othersUS$118.3MUS$62.60M13.6×2.5×−214.8%0.0×1.63

Forecasts

5 strong buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
22.00 USD · Analysts' mean
EPS, year to Dec 2026
-3.87 · 2 analysts
Revenue, year to Dec 2026
38.08M · 5 analysts

Team and board

Officers

OfficerRole
Kathleen GallagherChief Executive Officer
Brendan WinslowChief Financial Officer
Husam S. YounisChief Scientific Officer
Rocio Martin HoyosChief Strategy Officer
Stephanie KenneyChief Corporate Affairs Officer
Steve HughesChief Medical Officer

Board

DirectorRole
Sarah BoyceChair
Carsten BoessDirector
Kath GallagherDirector
Kathleen GallagherChief Executive Officer
Simona SkerjanecDirector
Troy WilsonDirector
W. Michael FlanaganDirector

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026 · After close+0.1%
Q2 2026Aug 13, 2026 · After close+4.1%
Q1 2026May 14, 2026 · After close−0.3%
Q4 2025Feb 23, 2026 · After close
Q3 2025Nov 10, 2025 · After close
Q2 2025Aug 7, 2025 · After close
Q1 2025May 8, 2025 · After close
Q4 2024Feb 26, 2025 · Before open
Q3 2024Nov 7, 2024 · After close
Q2 2024Aug 9, 2024 · After close
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · After close
Q4 2023Feb 28, 2024 · After close
Q3 2023Nov 8, 2023 · After close
Q2 2023Aug 8, 2023 · After close
Q1 2023May 9, 2023 · After close
Q4 2022Feb 28, 2023 · After close
Q3 2022Nov 8, 2022 · After close
Q2 2022Aug 9, 2022 · After close
Q1 2022May 10, 2022 · After close
Q4 2021Mar 1, 2022 · After close

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck28 slidesNov 12, 2026
Investor Presentation (October 2026)Investor deck27 slidesOctober 2026
Investor Presentation (August 2026)Investor deck27 slidesAugust 2026

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2013FY2012
Revenue18.6M10.9M9.56M9.22M9.33M6.79M2.32M379.0K13.1M10.4M
Cost of revenue4.15M2.78M2.10M1.39M639.0K37.6M14.5M8.44M32.5M22.7M
Gross profit18.6M10.9M7.46M9.22M9.33M6.79M2.32M-8.06M-19.4M-12.4M
Research and development53.8M303.6M191.0M150.4M101.2M37.6M14.5M8.44M25.4M19.0M
Selling, general and administrative41.7M86.2M54.2M37.7M26.2M13.5M5.11M2.44M
Operating income-76.8M-378.9M-235.6M-178.9M-118.1M-44.3M-17.3M-10.5M
Depreciation and amortization323.0K2.78M2.10M1.39M639.0K373.0K348.0K383.0K
EBITDA-76.5M-376.2M-233.5M-177.5M-117.4M-43.9M-17.0M-10.1M
Interest expense5.69M639.0K209.0K7.39M718.0K00
Income before tax-76.8M-322.3M-212.2M-174.0M-118.0M-44.4M-24.7M-11.2M
Income tax-142.0K1.93M-4.92M-639.0K-373.0K7.39M718.0K
Net income-76.7M-322.3M-212.2M-169.1M-117.4M-44.0M-24.7M-11.9M
Earnings per share, basic-4.48-2.89-2.91-3.24-2.83-2.03-0.66-0.58

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2013FY2012
Cash and equivalents270.0M219.9M185.1M340.4M320.4M328.1M94.6M3.09M113.3M53.7M
Short-term investments1.31B1.28B410.3M270.3M85.1M6.68M
Receivables12.4M28.2M8.62M3.88M900.0K1.20M800.0K
Inventory-7.33M1-900.0K-1.20M1
Current assets272.8M1.54B611.3M622.9M411.1M331.7M95.7M3.24M
Property, plant and equipment15.0M15.6M1.92M631.0K702.0K3.00M3.19M
Total assets278.4M1.56B628.6M638.8M427.6M333.9M96.9M3.98M125.1M62.4M
Accounts payable4.40M8.46M8.81M4.64M2.81M7.75M2.31M1.56M2.63M3.15M
Current liabilities41.8M98.0M80.7M51.9M29.7M14.6M10.2M4.62M12.5M16.1M
Long-term debt1.77M7.58M10.5M8.17M
Total debt3.67M6.80M9.85M10.7M11.7M938.0K4.94M10.3M
Total liabilities71.1M138.9M127.8M60.7M46.1M27.7M162.3M45.1M38.0M41.9M
Shareholders' equity207.3M1.42B500.8M578.1M381.4M306.2M-65.4M-41.1M87.1M20.5M
Shares outstanding17.1M111.6M73.0M52.2M41.4M21.7M37.5M20.7M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2013FY2012
Cash from operations-41.1M-300.9M-119.1M-136.3M-94.8M-37.1M2.49M-9.65M
Capital spending-1.45M-7.07M-4.23M-2.82M-3.74M-1.09M-235.0K-49.0K-834.0K-309.0K
Free cash flow-42.6M-307.9M-123.3M-139.1M-98.6M-38.2M2.25M-9.70M
Cash from investing-1.45M-854.2M-130.1M-190.0M-82.5M-7.79M-235.0K-49.0K
Cash from financing42.6M1.19B93.9M346.2M176.3M272.0M89.2M5.14M88.0M34.3M
Dividends paid0-444.0K-106.0K-106.0K
Share buybacks444.0K72.7M162.0K
Change in cash162.7M37.3M-155.3M19.9M-1.01M227.1M91.5M-4.56M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
8-K · Current reportNov 12, 2026ResultsSEC
8-K · Current reportNov 2, 2026Current reportSEC
8-K · Current reportOct 27, 2026Current reportSEC
8-K/A · Current report, amendedOct 9, 2026Current reportSEC
8-K · Current reportOct 8, 2026Material contractSEC
4 · Change in ownershipSep 22, 2026Insider tradeSEC
4 · Change in ownershipSep 22, 2026Insider tradeSEC
4 · Change in ownershipSep 22, 2026Insider tradeSEC
All 61 filings
FilingDateTypeFiled with
4 · Change in ownershipSep 22, 2026Insider tradeSEC
4 · Change in ownershipSep 22, 2026Insider tradeSEC
4 · Change in ownershipSep 22, 2026Insider tradeSEC
4 · Change in ownershipSep 22, 2026Insider tradeSEC
4 · Change in ownershipSep 22, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
8-K · Current reportAug 13, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 27, 2026Big-stake noticeSEC
8-K · Current reportJul 14, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
8-K · Current reportMay 14, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeApr 27, 2026Big-stake noticeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
S-8 · Registration statement for employee plansApr 17, 2026Offer documentSEC
SCHEDULE 13G · Big-stake noticeApr 8, 2026Big-stake noticeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
8-K · Current reportFeb 27, 2026Material contractSEC
3 · Initial statement of ownershipFeb 26, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 26, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 26, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 26, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 26, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 26, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 26, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 26, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 26, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 26, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 26, 2026Insider tradeSEC
8-K · Current reportFeb 26, 2026Current reportSEC
S-8 · Registration statement for employee plansFeb 26, 2026Offer documentSEC
SEC STAFF ACTIONFeb 26, 2026Other filingsSEC
CERT · Exchange's certificate of listingFeb 26, 2026Other filingsSEC
CORRESP · Letter to the SECFeb 24, 2026Other filingsSEC
10-12B/AFeb 17, 2026Other filingsSEC
CORRESP · Letter to the SECJan 29, 2026Other filingsSEC
10-12B/AJan 29, 2026Other filingsSEC
UPLOAD · Letter from the SECJan 27, 2026Other filingsSEC
10-12BDec 10, 2025Other filingsSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Atrium Therapeutics, Inc.’s releases

Common shares
17,105,643
Fully diluted
17,105,643

Fully diluted

LineShares
Common shares17,105,643

Share count over time

CountShares
Nov 22, 202617,105,643

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Sessa Capital IM, L.P.1.5M8.8%US$12.4MSep 30, 2026
BlackRock1.22M7.1%US$10.1MSep 30, 2026
Vanguard949K5.5%US$7.86MSep 30, 2026
T. Rowe Price640K3.7%US$5.3MSep 30, 2026
O'Connor Alternative Investments, LLC559K3.3%US$4.63MSep 30, 2026
Bracebridge Capital, LLC524K3.1%US$4.34MSep 30, 2026
TIG Advisors, LLC507K3.0%US$4.2MSep 30, 2026
Bank of America468K2.7%US$3.87MSep 30, 2026
Two Sigma427K2.5%US$3.54MSep 30, 2026
Geode Capital380K2.2%US$3.15MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Schonfeld Strategic Advisors LLC332K1.9%US$2.75MSep 30, 2026
Los Angeles Capital Management LLC321K1.9%US$2.66MSep 30, 2026
Arbiter Partners Capital Management LLC312K1.8%US$2.58MSep 30, 2026
Goldman Sachs300K1.8%US$2.49MSep 30, 2026
DAFNA Capital Management LLC300K1.8%US$2.48MSep 30, 2026
State Street291K1.7%US$2.41MSep 30, 2026
ADAR1 Capital Management, LLC268K1.6%US$2.22MSep 30, 2026
Citadel218K1.3%US$1.81MSep 30, 2026
BlueCrest Capital Management Ltd200K1.2%US$1.66MSep 30, 2026
Quantinno Capital Management LP179K1.0%US$1.48MSep 30, 2026
Yakira Capital Management, Inc.178K1.0%US$1.48MSep 30, 2026
Polar Asset Management Partners Inc.163K0.95%US$1.35MSep 30, 2026
Nexpoint Asset Management, L.P.150K0.88%US$1.24MSep 30, 2026
AWM Investment Company, Inc.150K0.88%US$1.24MSep 30, 2026
Millennium148K0.86%US$1.22MSep 30, 2026
Tudor Investment Corp Et Al141K0.82%US$1.17MSep 30, 2026
Nomura137K0.80%US$1.14MSep 30, 2026
Schwab137K0.80%US$1.13MSep 30, 2026
Northern Trust119K0.69%US$982KSep 30, 2026
Groupe la Francaise116K0.68%US$963KSep 30, 2026
Credit Industriel Et Commercial114K0.66%US$942KSep 30, 2026
Kalehua Capital Management LLC113K0.66%US$933KSep 30, 2026
Squarepoint Ops LLC113K0.66%US$932KSep 30, 2026
Cantor Fitzgerald, L. P.111K0.65%US$922KSep 30, 2026
Athos Capital Ltd108K0.63%US$894KSep 30, 2026
Qube Research & Technologies Ltd107K0.62%US$882KSep 30, 2026
Marble Bar Asset Management LLP104K0.61%US$860KSep 30, 2026
Balyasny Asset Management L.P.102K0.60%US$845KSep 30, 2026
Adage Capital Partners Gp, L.L.C.100K0.58%US$828KSep 30, 2026
Morgan Stanley80,1120.47%US$663KSep 30, 2026
Acadian Asset Management LLC78,8340.46%US$648KSep 30, 2026
Jacobs Levy Equity Management, Inc67,5650.39%US$559KSep 30, 2026
Jane Street63,7520.37%US$528KSep 30, 2026
ExodusPoint Capital Management, LP62,2270.36%US$515KSep 30, 2026
Kennedy Capital Management LLC61,2550.36%US$507KSep 30, 2026
Prelude Capital Management, LLC60,4380.35%US$500KSep 30, 2026
Marshall Wace, LLP59,3270.35%US$491KSep 30, 2026
Trium Capital LLP58,3820.34%US$483KSep 30, 2026
Fidelity55,8920.33%US$463KSep 30, 2026
Mercer Global Advisors Inc48,1500.28%US$399KSep 30, 2026

This page holds 50 of 144 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
T. Rowe Price Health Sciences Fund, Inc.566K3.3%US$7.62MJun 30, 2026
Vanguard Total Stock Market Index Fund518K3.0%US$6.97MJun 30, 2026
T. Rowe Price New Horizons Fund, Inc.443K2.6%US$5.96MJun 30, 2026
iShares Russell 2000 ETF377K2.2%US$5.08MJun 30, 2026
Vanguard Extended Market Index Fund189K1.1%US$2.54MJun 30, 2026
BlackRock Event Driven Equity Fund175K1.0%US$2.28MMay 29, 2026
Fidelity Small Cap Index Fund154K0.90%US$1.75MJul 31, 2026
Nexpoint Merger Arbitrage Fund135K0.79%US$1.82MJun 30, 2026
iShares Russell 2000 Growth ETF88,1070.52%US$1.19MJun 30, 2026
Fidelity Extended Market Index Fund73,5330.43%US$956KMay 31, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Schwab U.S. Small-Cap ETF67,6390.40%US$879KMay 31, 2026
Vanguard Russell 2000 Index Fund62,8890.37%US$818KMay 31, 2026
iShares Micro-Cap ETF48,1840.28%US$648KJun 30, 2026
T. Rowe Price Health Sciences Portfolio41,7000.24%US$561KJun 30, 2026
iShares Russell 2000 Value ETF41,0900.24%US$553KJun 30, 2026
Schwab Small-Cap Index Fund35,1180.21%US$399KJul 31, 2026
Master Small Cap Index Series28,3680.17%US$382KJun 30, 2026
Fidelity Total Market Index Fund26,5290.16%US$345KMay 31, 2026
Fidelity Series Total Market Index Fund21,2400.12%US$276KMay 31, 2026
Nuveen Small Cap Blend Index Fund19,8640.12%US$225KJul 31, 2026
iShares Core S&P Total U.S. Stock Market ETF18,5300.11%US$249KJun 30, 2026
EQ/2000 Managed Volatility Portfolio17,7810.10%US$239KJun 30, 2026
Fidelity SAI Merger Arbitrage Fund15,0000.09%US$170KJul 31, 2026
Putnam Dynamic Asset Allocation Growth Fund14,9080.09%US$201KJun 30, 2026
Health Sciences Trust14,9000.09%US$200KJun 30, 2026
AlphaCentric Life Sciences and Healthcare Fund13,4780.08%US$181KJun 30, 2026
BlackRock Advantage Small Cap Core Fund12,2370.07%US$159KMay 29, 2026
Fidelity Enhanced Small Cap Core ETF11,1120.06%US$149KJun 30, 2026
Vanguard Russell 2000 Growth Index Fund10,5240.06%US$137KMay 31, 2026
EQ/T.Rowe Price Health Sciences Portfolio10,4000.06%US$140KJun 30, 2026
Putnam Dynamic Asset Allocation Balanced Fund10,1760.06%US$137KJun 30, 2026
Goldman Sachs Absolute Return Tracker Fund10,0780.06%US$136KJun 30, 2026
NexPoint Event Driven Fund10,0330.06%US$135KJun 30, 2026
Ultra-Small Company Market Fund10,0000.06%US$135KJun 30, 2026
Nuveen Equity Index Fund9,6120.06%US$109KJul 31, 2026
Fidelity Small Cap Growth Index Fund9,1780.05%US$123KJun 30, 2026
Fidelity Nasdaq Composite Index Fund8,9980.05%US$117KMay 31, 2026
Vanguard Total World Stock Index Fund8,7600.05%US$99,426Jul 31, 2026
Goldman Sachs Small Cap Growth Insights Fund8,6360.05%US$98,019Jul 31, 2026
EQ/Small Company Index Portfolio8,3800.05%US$113KJun 30, 2026
Multi-Manager Small Cap Equity Strategies Fund8,3220.05%US$108KMay 31, 2026
Fidelity ZERO Total Market Index Fund8,2490.05%US$93,626Jul 31, 2026
Schwab U.S. Broad Market ETF8,2260.05%US$107KMay 31, 2026
Vanguard Balanced Index Fund8,1590.05%US$110KJun 30, 2026
LVIP State Street Small-Cap Index Fund7,8500.05%US$106KJun 30, 2026
Small Cap Index Fund7,4360.04%US$100KJun 30, 2026
Schwab Total Stock Market Index Fund7,0370.04%US$79,870Jul 31, 2026
Vanguard Institutional Total Stock Market Index Fund6,8700.04%US$92,402Jun 30, 2026
Global X Russell 2000 ETF6,8370.04%US$77,600Jul 31, 2026
Fidelity ZERO Extended Market Index Fund6,1450.04%US$69,746Jul 31, 2026

This page holds 50 of 149 holders. Open Shareholders

Big stakes

StakeStakeSharesDateFiling
Sessa Capital IM, L.P.8.80%1.5MJun 30, 2026Schedule 13G
BlackRock, Inc.6.60%1.14MJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Carsten Boess
Other companies: Avidity Biosciences, Inc (Director · Since at least Jun 11, 2020); Rocket Pharmaceuticals, Inc. (Director · Since at least Jan 11, 2016); Orchestra BioMed Holdings, Inc. (Director · Aug 3, 2020 – Aug 3, 2020 · Past); Synageva BioPharma Corp (SVP, Chief Financial Officer · Nov 2, 2011 – Jun 22, 2015 · Past); Insulet Corporation (Vice President, International · May 14, 2007 – Apr 25, 2011 · Past)
Director · Since at least Nov 10, 2025
Troy Wilson
Other companies: Avidity Biosciences, Inc (Director · Since at least Jun 11, 2020); Kura Oncology, Inc. (Chairman · Since at least Mar 6, 2015); Puma Biotechnology Inc (Director · Since at least Oct 18, 2013); Zosano Pharma Corp (Director · Jan 26, 2015 – Jan 2, 2019 · Past)
Director · Since at least Nov 10, 2025
Steven George Hughes
Other companies: Avidity Biosciences, Inc (Chief Medical Officer · Since at least Jan 6, 2025); Arcturus Therapeutics Holdings Inc. (Chief Development Officer · Feb 18, 2020 – Dec 18, 2020 · Past); VivoSim Labs, Inc. (Chief Medical Officer · Aug 1, 2018 – Aug 16, 2019 · Past)
Chief Medical Officer · Since at least Feb 26, 2026
Simona Skerjanec
Other companies: Immunic, Inc. (Director · Since at least Jul 22, 2024); Avidity Biosciences, Inc (Director · Since at least May 14, 2024)
Director · Since at least Nov 10, 2025
W. Michael Flanagan
Other companies: Avidity Biosciences, Inc (Chief Scientific Officer · Since at least Jan 21, 2021)
Director · Since at least Nov 10, 2025
Brendan WinslowChief Financial Officer · Since at least Feb 26, 2026
Husam S. YounisChief Scientific Officer · Since at least Feb 26, 2026
Kath GallagherDirector · Since at least Nov 4, 2026
Kathleen GallagherChief Executive Officer · Since at least Sep 22, 2026
Rocio Martin HoyosChief Strategy Officer · Since at least Apr 20, 2026
All 13 people
PersonSeat
Sarah BoyceChair · Since at least Feb 27, 2026
Stephanie KenneyChief Corporate Affairs Officer · Since at least Apr 20, 2026
Steve HughesChief Medical Officer · Since at least Jul 28, 2025

Open People

Log in to ask 6ix AI your own questions about Atrium Therapeutics, Inc.